Azithromycin cuts pulmonary exacerbation in CF with early Pseudomonas aeruginosa

Azithromycin cuts pulmonary exacerbation in CF with early <i>Pa</i>

(HealthDay)—For children with cystic fibrosis (CF) and early Pseudomonas aeruginosa (Pa) infection, the risk of pulmonary exacerbation is significantly reduced with the addition of azithromycin to tobramycin inhalation solution (TIS), according to a study published online June 11 in the American Journal of Respiratory and Critical Care Medicine.

Nicole Mayer-Hamblett, Ph.D., from the University of Washington in Seattle, and colleagues conducted a randomized trial in ages 6 months to 18 years with CF and early Pa. Children were given (110 participants) or placebo (111 participants) three times weekly in addition to standardized TIS.

The trial reached the pre-specified interim boundary for efficacy, and consequently, enrollment was stopped early by the National Heart, Lung, and Blood Institute. The researchers found that compared with placebo, the risk of pulmonary exacerbation was significantly reduced by 44 percent in the azithromycin group. There was a significant 1.27 kg increase in weight in the azithromycin versus the group. There were no significant differences in microbiologic or other clinical or safety end points.

"Azithromycin was associated with a significant reduction in risk of pulmonary exacerbation and sustained improvement in weight but had no impact on microbiologic outcomes in children with early Pa," the authors write.

Explore further

Azithromycin tied to poor airflow decline-free survival after HSCT

More information: Abstract/Full Text (subscription or payment may be required)

Copyright © 2018 HealthDay. All rights reserved.

Citation: Azithromycin cuts pulmonary exacerbation in CF with early Pseudomonas aeruginosa (2018, June 28) retrieved 13 November 2019 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments